Tenax Therapeutics, Inc. (TENX) Stock Grade

About Tenax Therapeutics, Inc.'s fundamentals

Tenax Therapeutics is a small-cap biotechnology company with a market capitalization of $49.1 million that reported no revenue growth year-over-year and maintained a net margin of 0.0% while posting a net loss in its latest annual statement. The company does not pay a dividend and lacks meaningful profitability metrics such as a P/E ratio and return on equity, which is typical for early-stage biotech firms. These fundamentals indicate the company is in a pre-revenue or minimal-revenue stage of development, relying on capital for research and development rather than generating earnings.